Atomo Diagnostics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Atomo Diagnostics şirketinin toplam hissedar öz sermayesi A$10.1M ve toplam borcu A$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$11.4M ve A$1.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	n/a
Nakit	AU$3.69m
Eşitlik	AU$10.08m
Toplam yükümlülükler	AU$1.29m
Toplam varlıklar	AU$11.38m

Son finansal sağlık güncellemeleri

We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow

Jul 19

Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business

Jan 22

Recent updates

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

Jul 05

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

Oct 10

Is Atomo Diagnostics (ASX:AT1) In A Good Position To Invest In Growth?

Jun 10

We're Not Worried About Atomo Diagnostics' (ASX:AT1) Cash Burn

Dec 06

Atomo Diagnostics Limited (ASX:AT1) Shares Could Be 50% Below Their Intrinsic Value Estimate

Nov 01

We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow

Jul 19

Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)

Feb 26

Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business

Jan 22

Here's What Atomo Diagnostics Limited's (ASX:AT1) Shareholder Ownership Structure Looks Like

Dec 18

When Can We Expect A Profit From Atomo Diagnostics Limited (ASX:AT1)?

Jul 16

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: AT1 'nin kısa vadeli varlıkları ( A$7.6M ) kısa vadeli yükümlülüklerini ( A$1.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: AT1 şirketinin kısa vadeli varlıkları ( A$7.6M ) uzun vadeli yükümlülüklerini ( A$106.5K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: AT1 borçsuzdur.

Borcun Azaltılması: AT1 şu anda borcu yok ancak 5 yıl öncesine ait verimiz olmadığı için karşılaştırma yapamıyoruz.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: AT1 şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 1.5 oranında tarihsel oranda büyümeye devam ederse AT1 un bir yıldan az nakit akışı süresi vardır.

Atomo Diagnostics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

Is Atomo Diagnostics (ASX:AT1) In A Good Position To Invest In Growth?

We're Not Worried About Atomo Diagnostics' (ASX:AT1) Cash Burn

We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow

Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business

Recent updates

Atomo Diagnostics Limited Receives A $2.44 Million Cooperative Research Centres Projects Grant to Spearhead the Development of A Groundbreaking Rapid Test for Active Syphilis Diagnosis

Atomo Diagnostics Limited, Annual General Meeting, Nov 15, 2024

Full year 2024 earnings released: AU$0.011 loss per share (vs AU$0.017 loss in FY 2023)

Atomo Diagnostics Limited to Report Q2, 2025 Results on Jan 31, 2025

New minor risk - Share price stability

Atomo Diagnostics Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Atomo Diagnostics Limited to Report First Half, 2024 Results on Jan 29, 2024

Atomo Diagnostics Limited Announces the Resignation of Curt LaBelle as Non-Executive Director

Atomo Diagnostics Limited Announces the Departure of William Souter as Chief Financial Officer, Effective 13 December 2023

Atomo Diagnostics Limited Announces the Departure of William Souter as Chief Financial Officer, Effective 13 December 2023

New major risk - Market cap size

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.01 loss in FY 2022)

Atomo Diagnostics Limited, Annual General Meeting, Nov 02, 2023

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

New major risk - Share price stability

Atomo Diagnostics Limited to Report Q4, 2023 Results on Jul 31, 2023

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.004 loss in 1H 2022)

Atomo Diagnostics Limited Appoints Cheri Walker as an Independent Non-Executive Director

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

Atomo Diagnostics Limited, Annual General Meeting, Oct 27, 2022

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Atomo Diagnostics (ASX:AT1) In A Good Position To Invest In Growth?

Forecast breakeven date pushed back to 2024

Atomo Diagnostics Limited Expands Executive Team

No longer forecast to breakeven

First half 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$0.31

Atomo Diagnostics Limited to Report First Half, 2022 Results on Feb 21, 2022

Atomo Diagnostics Limited Receives Approval for its Covid-19 Antigen Test in NZ

We're Not Worried About Atomo Diagnostics' (ASX:AT1) Cash Burn

Atomo Diagnostics Limited (ASX:AT1) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2021 earnings released

Consensus revenue estimates fall to AU$7.20m

Forecast breakeven pushed back to 2023

We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow

Consensus revenue estimates fall to AU$9.60m

Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)

First half 2021 earnings released: AU$0.005 loss per share (vs AU$0.008 loss in 1H 2020)

Revenue and earnings beat expectations

New 90-day low: AU$0.28

Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business

New 90-day low: AU$0.29

Here's What Atomo Diagnostics Limited's (ASX:AT1) Shareholder Ownership Structure Looks Like

New 90-day low: AU$0.30

Atomo Diagnostics Limited Receives TGA Approval for Atomorapid HIV (1&2) Test

Atomo Diagnostics Limited Receives TGA Approval for Covid19 Antigen Test

New 90-day low: AU$0.33

Atomo Diagnostics Limited Expands Its Existing COVID-19 Rapid Test Partnership with Access Bio LLC

Atomo Diagnostics Limited Enters into an Agreement DIVOC Laboratories to Launch its COVID-19 Antibody Test in the Indian Market

Full year earnings released - AU$0.026 loss per share

Atomo Diagnostics Limited to Report Fiscal Year 2020 Final Results on Nov 02, 2020

New 90-day high - AU$0.45

Atomo Diagnostics Limited to Report Fiscal Year 2020 Results on Aug 31, 2020

When Can We Expect A Profit From Atomo Diagnostics Limited (ASX:AT1)?

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin